Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| Unité 942 INSERM | Other Identifier | CCTIRS number 10.103 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Assistance Publique - Hôpitaux de Paris | OTHER |
| University Paris 7 - Denis Diderot | OTHER |
| ThermoFisher Scientific Brahms Biomarkers France | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this work is to investigate and then to sequence new biomarkers in the plasma of patients presenting with dyspnea secondary or not to heart failure, and study their diagnostic and prognostic value.
Plasma samples for patients with dyspnea, edema, with or without heart failure; ambulatory or admitted for cardiac decompensation (even with cardiac shock and LVAD) ; or entering a cardiac rehabilitation program, will be prospectively collected.
The objective of this work is to investigate and then to sequence new proteins in the plasma of these patients for diagnostic and prognostic purpose.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dyspnea cohort | Dyspnea cohort | ||
| Stable chronic heart failure | Stable chronic heart failure | ||
| Valvular heart disease | Valvular heart disease | ||
| Ventricular assist device | Ventricular assist device | ||
| Cardiac arrest | Cardiac arrest | ||
| Cardiac rehabilitation | Cardiac rehabilitation |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Long term cardiovascular mortality | To detect prognostic values of plasma biomarkers, we assess cardiovascular mortality at 3, 6, and 24 months. | Prospective at 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Cardiac hospitalization(s) at 3, 6,12 and 24 months | We assess cardiac morbidity within 3, 6, and 24 months months after admission | Prospective at 12 months |
| Diagnostic value of new biomarkers. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients presenting with dyspnea secondary or not to heart failure. Patients with dyspnea, edema, with heart failure, ambulatory or admitted for cardiac decompensation (even with cardiac shock and LVAD) ; or entering a cardiac rehabilitation program, will be prospectively collected.
Patients with valvular disease or with chronic heart failure.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Alexandre Mebazaa, PHD | Contact | +33(0)149958071 | alexandre.mebazaa@lrb.aphp.fr | |
| Alain Cohen-Solal, PHD | Contact | +33(0)149956608 | alain.cohen-solal@lrb.aphp.fr |
| Name | Affiliation | Role |
|---|---|---|
| Alain Cohen-Solal, PHD | Institut National de la Santé Et de la Recherche Médicale, France | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Lariboisiere hospital | Recruiting | Paris | Île-de-France Region | 75475 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32248819 | Derived | Badoz M, Arrigo M, Mogenet AC, Sadoune M, Meneveau N, Mebazaa A, Seronde MF. Assessment of successful percutaneous mitral commissurotomy by MRproANP and sCD146. BMC Cardiovasc Disord. 2020 Apr 5;20(1):157. doi: 10.1186/s12872-020-01435-y. | |
| 28516737 | Derived | Van Aelst LNL, Abraham M, Sadoune M, Lefebvre T, Manivet P, Logeart D, Launay JM, Karim Z, Puy H, Cohen-Solal A. Iron status and inflammatory biomarkers in patients with acutely decompensated heart failure: early in-hospital phase and 30-day follow-up. Eur J Heart Fail. 2017 Aug;19(8):1075-1076. doi: 10.1002/ejhf.837. Epub 2017 May 17. No abstract available. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| D004417 | Dyspnea |
| D008171 | Lung Diseases |
| D006331 | Heart Diseases |
| ID | Term |
|---|---|
| D002318 | Cardiovascular Diseases |
| D012120 | Respiration Disorders |
| D012140 | Respiratory Tract Diseases |
| D012818 | Signs and Symptoms, Respiratory |
Not provided
Not provided
| Hoffmann-La Roche |
| INDUSTRY |
| Alere San Diego | INDUSTRY |
| Servier | INDUSTRY |
| Helsinki University Central Hospital | OTHER |
| University Hospital, Basel, Switzerland | OTHER |
| Massachusetts General Hospital | OTHER |
| The Cleveland Clinic | OTHER |
| Maastricht University Medical Center | OTHER |
| Department of Laboratory Medicine, Konventhospital Barmherzige Brueder, Linz, Austria | UNKNOWN |
| Hospital Universitario Virgen de la Arrixaca | OTHER |
| University Hospital Monastir, Tunis | OTHER |
| Università degli Studi di Brescia | OTHER |
| Intensive and Cardiac Care Unit, Nippon Medical School, Tokyo, Japan | UNKNOWN |
| Brno University Hospital | OTHER |
| University of Cape Town | OTHER |
Not provided
Not provided
Not provided
Biomarkers assessment in plasma at different times according to the study cohort.
Assess accuracy of new biomarkers to discriminate heart failure from non-heart failure (negative and positive predictive values)
| at day 0 |
| 25157115 | Derived | Vodovar N, Seronde MF, Laribi S, Gayat E, Lassus J, Boukef R, Nouira S, Manivet P, Samuel JL, Logeart D, Ishihara S, Cohen Solal A, Januzzi JL Jr, Richards AM, Launay JM, Mebazaa A; GREAT Network. Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure. Eur Heart J. 2014 Dec 21;35(48):3434-41. doi: 10.1093/eurheartj/ehu314. Epub 2014 Aug 24. |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |